Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 8/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.81 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.81 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.81 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | DRD2 | P14416 | 1/20 | 0.81 |
| ▸ | DRD1 | P21728 | 1/20 | 0.81 |
| ▸ | HTR2A | P28223 | 1/20 | 0.81 |
| ▸ | DRD3 | P35462 | 1/20 | 0.81 |
| ▸ | SCN1A | P35498 | 1/20 | 0.81 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.81 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pridinol SCHEMBL363996 | 0.98 | CHRM2 (0.97) | CHRM2CHRM1CYP2D6KCNH2HTR1A | |
| Pridinol SCHEMBL27496509 | 0.98 | CHRM2 (0.97) | CHRM2CHRM1CYP2D6KCNH2HTR1A | |
| Pridinol SCHEMBL29250415 | 0.98 | CHRM2 (0.97) | CHRM2CHRM1CYP2D6KCNH2HTR1A | |
| SCHEMBL5497586 | 0.92 | CYP2D6 (0.85) | CHRM2CHRM1CYP2D6KCNH2HTR1A | |
| Hydrochloric Acid SCHEMBL5501561 | 0.91 | CHRM2 (0.82) | CHRM2CHRM1CYP2D6KCNH2HTR1A | |
| Diphenidol SCHEMBL34469 | 0.90 | CHRM3 (1.00) | CHRM2CHRM1CYP2D6KCNH2HTR1A | |
| Pridinol SCHEMBL195084 | 0.89 | CYP2D6 (1.00) | CHRM2CHRM1CYP2D6KCNH2HTR1A | |
| Diphenidol SCHEMBL195192 | 0.88 | CHRM3 (1.00) | CHRM2CHRM1CYP2D6KCNH2HTR1A | |
| Pridinol SCHEMBL10786634 | 0.88 | CYP2D6 (0.87) | CHRM2CHRM1CYP2D6KCNH2HTR1A | |
| SCHEMBL10307554 | 0.88 | CHRM3 (0.97) | CHRM2CHRM1CYP2D6KCNH2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1837 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | SINTALICA S R L (IT) | 2026-05-21 | — | — | US | claimed |
| EP-4638419-A1 | NON-HALLUCINOGENIC TRYPTAMINE COMPOUNDS, PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sintalica S.r.l. (IT) | 2025-10-29 | — | — | EP | claimed |
| EP-4601627-A1 | COMPOSITION COMPRISING NOT PHOSPHORYLATED TRYPTAMINE, ANTIOXIDANTS, AND SUPPLEMENTS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| CN-114788137-B | Rotor of rotating electrical machine and method for manufacturing rotor of rotating electrical machine | 三菱电机株式会社 | 2025-02-25 | — | — | CN | claimed |
| CN-110627276-B | Photocatalytic degradation device and application method thereof | 江西科技学院 | 2024-07-23 | — | — | CN | claimed |
| US-12029715-B2 | Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof | UNIVERSITY OF DEBRECEN (HU) | 2024-07-09 | — | — | US | claimed |
| WO-2024134619-A1 | NON-HALLUCINOGENIC TRYPTAMINE COMPOUNDS, PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SINTALICA S.R.L. (IT) | 2024-06-27 | — | — | WO | claimed |
| US-20240166990-A1 | METHODS AND COMPOSITIONS FOR INCREASING PROTEIN EXPRESSION IN GENETICALLY ENGINEERED BACTERIA | AZITRA INC. | 2024-05-23 | — | — | US | claimed |
| WO-2024079645-A1 | COMPOSITION COMPRISING NOT PHOSPHORYLATED TRYPTAMINE, ANTIOXIDANTS, AND SUPPLEMENTS, AND PHARMACEUTICAL USES THEREOF | SINTALICA S.R.L. (IT) | 2024-04-18 | — | — | WO | claimed |
| CN-109787160-B | Flexible cable stripping device | 国网电力科学研究院武汉南瑞有限责任公司 | 2024-02-23 | — | — | CN | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5780055-A | BEAD PREPARED FROM MICROCRYSTALLINE CELLULOSE BY EXTRUSION-SPHERONIZATION AND FREEZE DRYING | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 1998-07-14 | — | — | US | claimed |
| WO-1998009597-A2 | CUSHIONING BEADS AND TABLET COMPRISING THE SAME CAPABLE OF FORMING A SUSPENSION | UNIVERSITY OF MARYLAND BALTIMORE (US) | 1998-03-12 | — | — | WO | claimed |
| EP-0819001-A1 | USE OF SUBSTITUTED PIPERIDINE OR PYRROLIDINE COMPOUNDS FOR TREATING SIGMA-RECEPTOR MODULATED DISORDERS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1998-01-21 | — | — | EP | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| WO-1996031208-A2 | USE OF SUBSTITUTED PIPERIDINE OR PYRROLIDINE COMPOUNDS FOR TREATING SIGMA-RECEPTOR MODULATED DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-10-10 | — | — | WO | claimed |
| EP-0361894-B1 | Loading and controlled release of amphiphatic molecules to and from liposomes | YISSUM RES DEV CO (IL) | 1994-11-09 | — | — | EP | claimed |
| EP-0361894-A2 | Loading and controlled release of amphiphatic molecules to and from liposomes | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1990-04-04 | — | — | EP | claimed |
| US-4728513-A | HEAT TREATED FOR STORAGE STABILITY | ZYMA SA (CH) | 1988-03-01 | — | — | US | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029715-B2 | Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof | RXRA, RXRG, RARA | CHRM2 2095/4885CHRM1 2199/4885CYP2D6 327/4885 |
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | HTR2B, BDNF, HTR3B | CHRM2 586/4885CHRM1 223/4885CYP2D6 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.